To include your compound in the COVID-19 Resource Center, submit it here.

ProQR tests IPO threshold

ProQR's backers, hot disease area could make it exception to preclin IPO rule

While investors typically see preclinical companies as being too early for the public markets, a few examples from the current IPO window hint that Dutch cystic fibrosis play ProQR Therapeutics B.V. could be another exception

Read the full 356 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers